Novel PD-1 Inhibitor Prolgolimab: Expanding Therapeutic Choices for Nonresectable/Metastatic Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Novel PD-1 Inhibitor Prolgolimab: Expanding Non-Resectable/Metastatic Melanoma Therapy Choice
Eur. J. Cancer 2021 May 01;149(xx)222-232, S Tjulandin, L Demidov, V Moiseyenko, S Protsenko, T Semiglazova, S Odintsova, R Zukov, S Lazarev, Y Makarova, M Nechaeva, D Sakaeva, A Andreev, A Tarasova, N Fadeyeva, M Shustova, I KuryshevFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.